Immunotherapies and targeted therapies in medical oncology

Bulletin du cancer
Benoît RousseauJean-Charles Soria

Abstract

New immunotherapies, also called "immune checkpoints", are promising and showed interesting antitumoral activities in particular in advanced setting of melanoma, clear cell renal cancer or non-small cell lung carcinoma. These treatments include ipilimumab, anti-PD-1 and anti-PD-L1. There is a strong rational for combination of immunotherapies and targeted therapies. This review is dedicated to expose the theorical issues and preclinical data of such combinations. This review examined the impact of immunotherapies on transduction pathways and modification of immunity related to targeted therapies. First clinical data form early drug development studies showed the difficulties observed with such combination and limitating toxicities. Finally, potential interesting combinations are overviewed with an emphasis on sequential treatments.

References

Oct 18, 2005·Molecular and Cellular Biology·Richard V ParryJames L Riley
Dec 17, 2009·The Journal of Experimental Medicine·Loise M FranciscoArlene H Sharpe
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Aug 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jahan S KhaliliGregory Lizée
Oct 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaofeng JiangF Stephen Hodi
Feb 9, 2013·The Journal of Clinical Investigation·Michael HebeisenNathalie Rufer
Mar 13, 2013·The Journal of Clinical Investigation·Chen WangJordan S Pober
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 6, 2013·Bulletin du cancer·Ecaterina IleanaJean-Charles Soria
Jul 31, 2013·Immunity·Daniel S Chen, Ira Mellman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved